Plaintiff

Jazz Pharmaceuticals Ireland Ltd.

20 cases as plaintiff.

Cases
20
Active
5
15 closed
Filed
2013–2026
Top venue
D. New Jersey
7 cases
Also appears as a defendant in 9 cases → View as defendant

Company profile

Jazz Pharmaceuticals Ireland Limited is an Irish operating subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a specialty biopharmaceutical company headquartered at Waterloo Exchange, Dublin 4, Ireland, with U.S. operations in Palo Alto, Carlsbad, Philadelphia and Durham. Jazz plc was incorporated in Ireland in 2005 as Azur Pharma and took its current name after the January 2012 merger with Jazz Pharmaceuticals, Inc. (founded 2003, California). Per its FY2025 Form 10-K it had approximately 2,890 employees worldwide and total revenues of $4.27 billion in 2025 (net loss $356 million). Reuters/GlobalData list market capitalization around $15 billion. Ownership is public; the Irish entity sits within the Jazz plc group.

The company develops and commercializes rare-disease medicines. Key products include the oxybate franchise Xywav and Xyrem (narcolepsy, idiopathic hypersomnia), Epidiolex/Epidyolex (cannabidiol for Lennox-Gastaut, Dravet and tuberous sclerosis complex epilepsies), and oncology/hematology drugs Zepzelca (lurbinectedin), Rylaze/Enrylaze, Defitelio, Vyxeos, Ziihera (zanidatamab) and Modeyso (dordaviprone). It also owns manufacturing sites in Athlone (Ireland), Kent (U.K.) and Villa Guardia (Italy).

Litigation posture: an operating company that litigates primarily as a brand plaintiff. Of 29 tracked cases, 20 are plaintiff suits — almost all Hatch-Waxman/ANDA infringement actions filed in the District of New Jersey (and Delaware) against generic filers including Lupin, Teva, Granules, Alkem, Tris Pharma, Amneal, Roxane, Wockhardt, Mallinckrodt and Ascent. The nine defendant appearances are defensive: the consolidated Xyrem antitrust MDL brought by purchasers (e.g., UFCW Local 1500 Welfare Fund), Avadel's Delaware counterclaims/antitrust and trade-secret suits, and three PTAB proceedings (Amneal, Ranbaxy, Par) in which six REMS patents were invalidated. Venues are New Jersey and Delaware, not the Eastern District of Texas.

Notable matters: the Avadel global settlement (October 2025) resolving mutual Delaware patent and antitrust claims, the resolved Xyrem antitrust MDL ($233.5 million charge in 2025), and the February 2026 Tris Pharma suits over Xyrem/Xywav referenced in the case list.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

Filing activity

2013: 1 case'132015: 4 cases4'152017: 1 case'172018: 1 case'192021: 3 cases'212023: 3 cases'232025: 1 case'252026: 1 case
Cases filed per year with Jazz Pharmaceuticals Ireland Ltd. as plaintiff.

Jazz Pharmaceuticals Ireland Ltd. v. Granules India Limited

judgment
Docket:
2:25-cv-14606
Court:
D.N.J.
Filed:
2025-08-13
Terminated:
2026-03-26
Patents:10213400

Jazz Pharmaceuticals Ireland Ltd. sued Granules India Limited; 14 patents were asserted including the '400 patent. The case was terminated by consent judgment dismissing with prejudice on 2026-03-26.

Jazz Pharmaceuticals Ireland Ltd. v. Alkem Laboratories Ltd.

dismissed
Docket:
2:23-cv-03182
Filed:
2023-06-09
Terminated:
2023-10-05

Jazz sued Alkem in a Xyrem-related ANDA action; the complaint asserted the '426 patent plus other patents. The case was voluntarily dismissed, with a Rule 41(a)(1)(A)(i) order signed Oct. 5, 2023, and the case terminated.

Jazz Pharmaceuticals Ireland Ltd. v. Teva Pharmaceuticals, Inc.

active
Docket:
2:23-cv-01617
Filed:
2023-03-21

Jazz sued Teva over Teva's ANDA for generic Xywav; the complaint lists the '426 patent among the patents-in-suit. Teva filed invalidity contentions and counterclaims; the case was consolidated with the Lupin actions on Dec. 15, 2023, and remains ongoing with no final judgment on '426 found.

Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC et al.

dismissed with prejudice
Docket:
1:21-cv-01594-GBW
Filed:
2021-11-10
Terminated:
2025-10-27
Patents:10272062

Patent infringement action involving Jazz Pharmaceuticals entities and Avadel entities; resolved in the same October 2025 global settlement and stipulation of dismissal with prejudice entered October 27, 2025.

Jazz Pharmaceuticals Ireland Ltd. v. Lupin Ltd. et al.

active
Docket:
2:21-cv-14271
Filed:
2021-07-28

Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.

Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al.

settled
Docket:
2:15-cv-05619
Filed:
2015-07-17
Patents:8457988

Jazz Pharmaceuticals and Jazz Pharmaceuticals Ireland sued Wockhardt entities in D.N.J. over ANDA No. 207526. Wockhardt filed counterclaims for declaratory judgment of invalidity/non-infringement of the '988 patent and others, and later settled before the Federal Circuit decision.

Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al.

dismissed
Docket:
2:15-cv-05619
Filed:
2015-07-17
Patents:8772306

Resolved by a stipulation/consent judgment of dismissal. Wockhardt admitted the ANDA filing was a technical act of infringement of the asserted patents, expressly including 8,772,306, and was enjoined except as permitted by the April 18, 2016 license agreement.

Jazz Pharmaceuticals, Inc. et al. v. Roxane Laboratories, Inc.

settled
Docket:
2:15-cv-01360
Filed:
2015-02-20
Patents:8772306

The '306 patent was asserted; Roxane moved to dismiss the '306 claims on §101 subject-matter eligibility, which the court administratively terminated and stayed discovery on pending IPR. The case was consolidated with Roxane's '302 case on Mar 24, 2016 and settled in April 2017.

Jazz Pharmaceuticals, Inc. et al. v. Watson Laboratories, Inc.

consolidated; resolved/terminated
Docket:
14-cv-07757
Court:
D.N.J.
Patents:6780889

D.N.J. Xyrem ANDA action against Watson, consolidated with the Ranbaxy and Amneal Xyrem actions for a 500 mg/ml generic sodium oxybate oral solution. The narrative identifies it among the Hatch-Waxman suits filed by Jazz on US 6,780,889; it was resolved/terminated in the 2015-2018 window.

Jazz Pharmaceuticals Ireland Ltd. v. Tris Pharma, Inc.

pending; motion to dismiss denied
Docket:
2:26-cv-01739
Patents:10864181

Jazz Pharmaceuticals Ireland Ltd. sued Tris Pharma, Inc. in the District of New Jersey. Judge Stanley R. Chesler denied Tris's motion to dismiss on July 8, 2026, and an answer, counterclaim, and scheduling order followed.